Similarly, doubled risk for all-cause mortality seen during five-year study period<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Nov. 6, 2025 (HealthDay News) — Long-term melatonin use for treatment of insomnia is associated with a higher risk for incident heart failure and all-cause mortality, according to a study to be presented at the American Heart Association Scientific Sessions 2025, being held from Nov. 7 to 10 in New Orleans.<\/p>\n
Ekenedilichukwu Nnadi, M.D., from SUNY Downstate\/Kings County Primary Care in Brooklyn, New York, and colleagues queried the TriNetX Global Research Network to compare long-term cardiovascular safety in adults with insomnia and at least one melatonin prescription and \u2265365 exposure-days versus those not exposed to melatonin. The analysis included 65,414 melatonin users and 65,414 controls matched for demographics, 15 comorbidities, concomitant cardiometabolic drugs, laboratories, vitals, and health care utilization.<\/p>\n
The researchers found that during five years of follow-up, incident heart failure occurred in 3,021 melatonin users (4.6 percent) versus 1,797 controls (2.7 percent; hazard ratio [HR], 1.89). A similar trend was seen for heart failure-related hospitalization, which occurred in 12,411 users (19.0 percent) and 4,309 controls (6.6 percent; HR, 3.44). Additionally, all-cause mortality was higher in melatonin users (7.8 versus 4.3 percent; HR, 2.09). Similar results were seen when the analysis was limited to two or more melatonin fills \u226590 days apart (HR for heart failure, 1.82).<\/p>\n
“Melatonin supplements may not be as harmless as commonly assumed,” Nnadi said in a statement. “If our study is confirmed, this could affect how doctors counsel patients about sleep aids.”<\/p>\n